Samsrita Labs

Why is Samsrita Labs Ltd falling/rising?

As of 01-Sep, Samsrita Labs Ltd's stock price is rising to 12.13, up 4.57%, driven by strong recent performance and increased investor interest, with an 8.89% gain over the past week. The stock has outperformed its sector and shows positive short-term momentum despite being below longer-term moving averages.

As of 01-Sep, Samsrita Labs Ltd's stock price is rising, currently at 12.13, reflecting an increase of 0.53 or 4.57%. This upward movement is supported by several factors. Over the past week, the stock has shown a significant gain of 8.89%, while the benchmark Sensex has declined by 0.92%. Additionally, in the last month, the stock has risen by 14.00%, contrasting with a 1.47% drop in the Sensex.<BR><BR>Today, the stock has outperformed its sector by 5.39% and has been on a consecutive gain streak for the last three days, accumulating a total return of 14.43% during this period. The stock's performance is also bolstered by rising investor participation, as evidenced by a delivery volume of 21.65k on August 31, which is a 37.89% increase compared to the 5-day average delivery volume. Furthermore, the stock's current price is higher than its 5-day, 20-day, and 50-day moving averages, indicating positive short-term momentum, although it remains below the 100-day and 200-day moving averages.<BR><BR>Overall, the combination of strong recent performance, increased investor interest, and positive short-term trends contributes to the rising price of Samsrita Labs Ltd.

Which are the latest news on Samsrita Labs?

Who are in the management team of Samsrita Labs?

The management team of Samsrita Labs includes K Krishnam Raju (Chairman & Wholetime Director), K.N.V Narendra Kumar (Whole Time Director & CFO), and several Independent Directors: B Suryaprakash Rao, Aakanksha, Ramamohan Reddy Yarragudi, and A.S.S.V.Srinivas, along with Deepa Dudani as Company Secretary & Compliance Officer.

The management team of Samsrita Labs includes the following individuals:<BR><BR>1. **K Krishnam Raju** - Chairman & Wholetime Director<BR>2. **B Suryaprakash Rao** - Independent Director<BR>3. **K.N.V Narendra Kumar** - Whole Time Director & CFO<BR>4. **Aakanksha** - Independent Director<BR>5. **Ramamohan Reddy Yarragudi** - Independent Director<BR>6. **A.S.S.V.Srinivas** - Independent Director<BR>7. **Deepa Dudani** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Samsrita Labs do?

Samsrita Labs Ltd is a micro-cap company in the healthcare services industry, originally founded as Dr Habeebullah Life Sciences Limited in 1996 and renamed in 2022. As of June 2026, it reported a net profit of 0 Cr and has a market cap of INR 25 Cr.

Overview:<BR>Samsrita Labs Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Samsrita Labs Ltd was originally incorporated as 'Dr Habeebullah Life Sciences Limited' in 1996. The company underwent a name change to Samsrita Labs Limited on October 13, 2022. The most recent quarterly results reported net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 25 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 21<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: -76.63%<BR>Price-to-Book: 2.22<BR><BR>Contact Details:<BR>Address: Sy No 36 Chintalmet X Roads, Upperpally Attapur Rajendra Ng Hyderabad Telangana : 500048<BR>Phone: 91-90300 57370<BR>Email: pcproductsindia@gmail.com<BR>Website: https://drhlsl.com

Who are the peers of the Samsrita Labs?

Samsrita Labs' peers include GKB Ophthalmics, Chennai Meena, Tejnaksh Health, Adeshwar Meditex, Transgene Biotek, Vanta Bioscience, Family Care, Dhanvantri Jeev, and Looks Health. Dhanvantri Jeev has the highest 1-year return at 26.19%, while Samsrita Labs has a return of -40.82%.

Peers: The peers of Samsrita Labs are GKB Ophthalmics, Chennai Meena, Tejnaksh Health., Adeshwar Meditex, Transgene Biotek, Vanta Bioscience, Family Care, Dhanvantri Jeev., and Looks Health.<BR><BR>Quality Snapshot: Below Average management risk is observed at GKB Ophthalmics, Tejnaksh Health., Adeshwar Meditex, Dhanvantri Jeev., and Vanta Bioscience, while Average management risk is found at Family Care. Chennai Meena, Samsrita Labs, Transgene Biotek, and Looks Health do not qualify for management risk. Good growth is noted at GKB Ophthalmics and Family Care, while Below Average growth is seen at Tejnaksh Health., Adeshwar Meditex, Vanta Bioscience, and Dhanvantri Jeev. Samsrita Labs, Chennai Meena, Transgene Biotek, and Looks Health do not qualify for growth. Good capital structure is present at GKB Ophthalmics, Tejnaksh Health., Family Care, and Dhanvantri Jeev., while Average capital structure is observed at Adeshwar Meditex, and Below Average at Vanta Bioscience.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Tejnaksh Health. has the lowest at -25.80%. Samsrita Labs' 1-year return is -40.82%, which is significantly lower than both. Additionally, peers such as Family Care, Transgene Biotek, and Vanta Bioscience have negative six-month returns.

How big is Samsrita Labs?

As of 31st August, Samsrita Labs Ltd has a market capitalization of 25.00 Cr and reported net sales of 0.02 Cr with a loss of 8.16 Cr over the latest four quarters. Shareholder's funds are 11.75 Cr, and total assets amount to 14.38 Cr.

As of 31st August, Samsrita Labs Ltd has a market capitalization of 25.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Samsrita Labs reported net sales of 0.02 Cr. However, the company faced a loss of 8.16 Cr during the same period.<BR><BR>For the reporting period of March 2026, the balance sheet shows shareholder's funds of 11.75 Cr and total assets amounting to 14.38 Cr.

When is the next results date for Samsrita Labs Ltd?

The next results date for Samsrita Labs Ltd is 13 August 2026.

The next results date for Samsrita Labs Ltd is scheduled for 13 August 2026.

How has been the historical performance of Samsrita Labs?

Samsrita Labs has experienced a declining trend in net sales, dropping from 2.01 Cr in March 2019 to 0.01 Cr in March 2021, alongside increasing losses, with an operating profit of -0.79 Cr in March 2021. The company's total liabilities and assets also decreased significantly during this period, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Samsrita Labs shows a declining trend in net sales and increasing losses over the years.<BR><BR>Breakdown:<BR>Samsrita Labs reported net sales of 0.01 Cr in March 2021, a significant drop from 1.43 Cr in March 2020 and 2.01 Cr in March 2019. The total operating income followed a similar trend, decreasing from 1.43 Cr in March 2020 to 0.01 Cr in March 2021. The company faced substantial losses, with an operating profit (PBDIT) of -0.79 Cr in March 2021, improving slightly from -2.03 Cr in March 2020 but still reflecting ongoing operational challenges. Profit before tax was recorded at -0.80 Cr in March 2021, compared to -2.05 Cr in the previous year, while profit after tax also showed a loss of -0.78 Cr, down from -1.98 Cr in March 2020. The company's total liabilities decreased from 27.75 Cr in March 2020 to 16.58 Cr in March 2021, with total assets also declining from 27.75 Cr to 16.58 Cr in the same period. Cash flow from operating activities remained stagnant, with no inflow or outflow reported in the last two years. Overall, the financial data indicates a challenging period for Samsrita Labs, characterized by declining revenues and persistent losses.

Is Samsrita Labs overvalued or undervalued?

As of April 25, 2023, Samsrita Labs is rated as "risky" and overvalued with a negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30, indicating significant financial struggles compared to peers like MMTC and Optiemus Infra, despite a recent 34.45% return.

As of 25 April 2023, Samsrita Labs has moved from a grade of "does not qualify" to "risky." The company is currently overvalued, as indicated by its negative PE ratio of -31.10 and an EV to EBIT ratio of -33.30. Additionally, the ROCE stands at -3.04%, which further highlights the company's financial struggles.<BR><BR>In comparison to peers, MMTC has a PE ratio of 119.39 and an EV to EBITDA of -70.04, while Optiemus Infra is considered fair with a PE ratio of 82.35 and an EV to EBITDA of 48.56. The stark contrast in these ratios suggests that Samsrita Labs is not only underperforming relative to its peers but also carries significant risk. Despite a recent 34.45% return over the past year, the overall valuation metrics indicate that the stock remains overvalued in the current market context.

What is the technical trend for Samsrita Labs?

As of May 12, 2025, Samsrita Labs shows a mildly bullish trend supported by positive MACD and KST indicators, despite some short-term weakness indicated by the RSI and daily moving averages.

As of 12 May 2025, the technical trend for Samsrita Labs has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bullish, indicating a gradual strengthening. The weekly KST is mildly bullish and the monthly KST is bullish, further reinforcing the upward momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are mildly bearish, which contrasts with the overall bullish sentiment. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential for price expansion. Overall, the current stance is mildly bullish, driven primarily by the MACD and KST indicators, despite some mixed signals from the RSI and moving averages.

Who are the top shareholders of the Samsrita Labs?

The top shareholders of Samsrita Labs are K Krishnam Raju with 19.58%, followed by M Neela Reddy at 4.67%, and individual investors collectively holding 44.75%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Samsrita Labs include K Krishnam Raju, who holds the highest promoter share at 19.58%. Following him, the highest public shareholder is M Neela Reddy, with a holding of 4.67%. Additionally, individual investors collectively hold 44.75% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Has Samsrita Labs declared dividend?

No Dividend History Available